LOS ANGELES, Aug. 3, 2026 /PRNewswire/ — Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celcuity Inc. (“Celcuity” or “the Company”) (NASDAQ: CELC) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Celcuity announced on July 14, 2026, that it had received FDA approval for its breast cancer treatment Revtorpyk (gedatolisib), adding that it “anticipates commercial launch in late Q3 2026,” a delayed timeframe compared to analyst expectations. Based on this news, shares of Celcuity fell by 17.6% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at david@schallfirm.com
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content:https://www.prnewswire.com/news-releases/celc-investors-have-opportunity-to-join-celcuity-inc-fraud-investigation-with-sbs-law-302840751.html
SOURCE Schall, Brown & Schwartz LLP
